Announcement Details

View all announcements

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc

(“Hemogenyx Pharmaceuticals” or the “Company”)

LEI 2138008L93GYU5GN6179


Director/PDMR Shareholding


Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company’s issued share capital.


Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1. Details of PDMR/person closely associated with them (“PCA”)
a) Name Andrew Wright
2. Reason for the notification
a) Position/status Financial Controller and Company Secretary
b) Initial notification/
Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Full name of the entity Hemogenyx Pharmaceuticals plc
b) Legal Entity Identifier code 2138008L93GYU5GN6179
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary shares of Hemogenyx Pharmaceuticals plc


b) Nature of the transaction Standalone acquisition of shares


c) Price(s) and volume(s)
Price(s) Volume(s)
GBP £0.0144 1,284,889


d) Aggregated information

– Aggregated volume

– Price

Price(s) Volume(s)
GBP £18,502.40 1,284,889
e) Date of the transaction 2022-05-27
f) Place of the transaction London Stock Exchange



Hemogenyx Pharmaceuticals plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow


View all announcements